Abbott Libre Duo

What is authorized. On 25 August 2026 the FDA authorized the prescription Libre Duo 10 Day for people with diabetes aged 2 and older, including adults. It measures interstitial glucose and beta-hydroxybutyrate, a ketone, with readings updated every minute. Ketone output must be interpreted with glucose, symptoms and factors such as eating and exercise; a ketone number alone is not a DKA diagnosis.¹²

Versions and observed wear. Abbott reports CE marking for Libre Duo, with up to 15-day wear for adults 18+, and Libre Duo 10 Day, with up to 10-day wear for ages 2+. The US authorization covered the 10-day version. Abbott’s US page reports that 84.1% of adult sensors and 68.8% of pediatric sensors lasted the full 10 days; underlying sensor counts and confidence intervals are not supplied on that page. Maximum wear is not guaranteed wear.⁵³²

What the clinical evidence establishes here. The FDA announcement reports six studies enrolling more than 600 participants aged 2+, and describes acceptable glucose and ketone tracking. It does not provide the detailed accuracy tables, endpoint-specific analysis populations or a DKA-reduction effect estimate. This review did not retrieve the full original performance manual, so it does not assign a glucose MARD, ketone-accuracy rate or numerical comparison with other sensors. Libre 3 accuracy cannot be assumed for this different device.¹²

Important safety limits. The US safety information requires blood-glucose meter confirmation before treatment decisions during the first 12 hours, while the sensor-may-be-inaccurate symbol is displayed, and when glucose readings do not match symptoms or expectations. Urgent alarms may miss glucose below 55 mg/dL or ketones above 3.0 mmol/L. Connection and phone settings affect alerts. The label says not to use the system during dialysis or critical illness, and warns that more than 1,000 mg of vitamin C daily can falsely raise sensor glucose. These are selected limitations; consult the full product instructions.⁴⁶

DKA prevention remains a research question. A 2025 original report describes historical episodic ketone testing and separate preliminary dual-sensor case studies; those should not be treated as a randomized prevention trial. A newer registered observational study, NCT07739342, targets 1,200 people with type 1 diabetes using an Abbott dual glucose-ketone system; the registry does not give the Libre Duo brand name. Its latest posted record, dated 31 July and checked here on 17 September 2026, still says not yet recruiting and has no posted results. It specifies three months of sensor use in the arm description but a 12-month primary-outcome timeframe, which remains unresolved. Neither publication context nor a planned study establishes that Duo prevents DKA.⁷⁸

Connected pumps are separate products. The FDA order permits communication with compatible digitally connected devices. It does not establish every named pump pairing or an algorithm that doses insulin from ketones. Abbott’s August announcement targets iLet and twiist integration by the end of 2026, and Insulet and Tandem in 2027. It separately describes an Abbott-manufactured dual sensor for MiniMed in 2027. These are company plans, not verified shipping combinations.²⁶

Access and scoring. Abbott’s US product page still says coming soon when checked on 17 September 2026. Its May and August releases announced later-2026 launches in select European countries and the US, respectively; this review has not confirmed country-by-country supply, pricing or reimbursement. The record stays in the pipeline listing and is unscored until sufficiently complete original performance evidence can support a comparable assessment.³⁵⁶